--- title: "Eli Lilly | 8-K: FY2026 Q3 Revenue: USD 24.4 B" type: "News" locale: "en" url: "https://longbridge.com/en/news/303551684.md" datetime: "2026-10-29T11:06:16.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/303551684.md) - [en](https://longbridge.com/en/news/303551684.md) - [zh-HK](https://longbridge.com/zh-HK/news/303551684.md) generator: "portal-rs" --- # Eli Lilly | 8-K: FY2026 Q3 Revenue: USD 24.4 B Revenue: As of FY2026 Q3, the actual value is USD 24.4 B, compared to the market estimate of USD 22.62 B. EPS: As of FY2026 Q3, the actual value is USD 7.22, compared to the market estimate of USD 8.0067. EBIT: As of FY2026 Q3, the actual value is USD 8.722 B. #### Revenue Eli Lilly and Company reported worldwide revenue of $24.4 billion in Q3 2026, marking a 39% increase compared to Q3 2025, primarily driven by Mounjaro and Zepbound . This growth included approximately $900 million in benefits, with $410 million from Jardiance milestones and favorable adjustments to rebate and discount estimates . The overall revenue increase was due to a 53% increase in volume, partially offset by a 15% decrease in realized prices . **U.S. Revenue**: Increased 34% to $15.1 billion, driven by a 41% volume increase, partially offset by a 7% decrease in realized prices . The volume increase was primarily from Zepbound and Mounjaro . **Revenue outside the U.S.**: Increased 47% to $9.3 billion, driven by a 76% volume increase, partially offset by a 29% decrease in realized prices . Mounjaro was the primary driver of international volume growth, while lower realized prices were influenced by Mounjaro’s inclusion on China’s National Reimbursement Drug List . **Key Products Revenue**: Totaled $17.1 billion in Q3 2026 . Revenue from Key Products in Immunology, Oncology, and Neuroscience therapeutic areas grew 100% in Q3 2026 compared to Q3 2025 . **Mounjaro**: Worldwide revenue increased 65% to $10.7 billion . U.S. revenue was $5.0 billion (41% increase), and revenue outside the U.S. increased 93% to $5.7 billion . **Zepbound**: U.S. revenue increased 48% to $5.3 billion . **Jaypirca**: $228 million (59% increase) . **Ebglyss**: $202 million (59% increase) . **Kisunla**: $193 million (175% increase) . **Omvoh**: $114 million (76% increase) . **Foundayo**: $184 million (NM change) . **Inluriyo**: $73 million (NM change) . #### Net Income - **Reported Net Income**: $6,451 million in Q3 2026, a 16% increase from $5,583 million in Q3 2025 . - **Non-GAAP Net Income**: $6,679 million in Q3 2026, a 6% increase from $6,312 million in Q3 2025 . #### Gross Margin - **Reported Gross Margin**: Increased 40% to $20,464 million in Q3 2026 . As a percentage of revenue, it was 83.9%, an increase of 1.0 percentage points year-over-year . - **Non-GAAP Gross Margin**: Increased 40% to $20,592 million in Q3 2026 . As a percentage of revenue, it was 84.4%, an increase of 0.8 percentage points year-over-year . The increase was primarily driven by favorable product mix and improved cost of production, partially offset by lower realized prices . #### Operating Costs and Expenses - **Cost of Sales**: $3,933 million in Q3 2026, a 31% increase from Q3 2025 . - **Research and Development Expenses**: Increased 23% to $4,247 million in Q3 2026, representing 17% of revenue . - **Marketing, Selling, and Administrative Expenses**: Increased 14% to $3,125 million in Q3 2026 . - **Acquired In-Process Research and Development (IPR&D) Charges**: Totaled $4,181 million in Q3 2026, compared to $656 million in Q3 2025, primarily related to acquisitions . - **Asset Impairment, Restructuring and Other Special Charges**: $303 million in Q3 2026, a -17% change from $365 million in Q3 2025 . #### Operating Income - **Reported Operating Income**: $8,608 million in Q3 2026, a 17% increase from $7,365 million in Q3 2025 . #### Other Financial Items - **Net Interest Income (Expense)**: - $316 million in Q3 2026, compared to - $114 million in Q3 2025 . - **Net Other Income (Expense)**: $114 million in Q3 2026, compared to - $18 million in Q3 2025 . - **Income Before Income Taxes**: $8,406 million in Q3 2026, a 16% increase from Q3 2025 . - **Income Tax Expense**: $1,955 million in Q3 2026, an 18% increase from Q3 2025 . - **Reported Effective Tax Rate**: 23.3% in Q3 2026, compared to 22.8% in Q3 2025 . - **Non-GAAP Effective Tax Rate**: 24.0% in Q3 2026, compared to 17.7% in Q3 2025 . - **Dividends Paid Per Share**: $1.73 in Q3 2026, a 15% increase from Q3 2025 . - **Weighted-Average Shares Outstanding (Diluted)**: 893,439 thousand in Q3 2026, compared to 898,804 thousand in Q3 2025 . #### Business Development Eli Lilly and Company completed the acquisition of AtaiBeckley to advance therapies for treatment-resistant depression and other mental health conditions in Q3 2026 . Subsequent to quarter end, the company completed the acquisition of Merida Biosciences to advance treatments for serious autoimmune and allergic diseases . #### Outlook / Guidance Eli Lilly and Company raised its full-year 2026 revenue guidance to a range of $91.0 to $92.0 billion . The company’s non-GAAP Performance Margin guidance increased to 52.0% to 52.5% . The non-GAAP effective tax rate guidance is now 19% to 20% . ### Related Stocks - [LLY.US](https://longbridge.com/en/quote/LLY.US.md) - [LLYX.US](https://longbridge.com/en/quote/LLYX.US.md) - [ELIL.US](https://longbridge.com/en/quote/ELIL.US.md) ## Related News & Research - [Eli Lilly CFO on acquisition spree: 'We are taking bets' on future revenue](https://longbridge.com/en/news/303613049.md) - [Eli Lilly and Company (NYSE:LLY) Shares Climb 3.1% Following Better-Than-Expected Earnings](https://longbridge.com/en/news/303803148.md) - [Lilly reports third-quarter 2026 financial results, raises full-year guidance and highlights regulatory progress across the portfolio | LLY Stock News](https://longbridge.com/en/news/303548458.md) - [Eli Lilly’s tirzepatide outperforms big pharma companies in Q3](https://longbridge.com/en/news/303737912.md) - [LLY Stock Hits Record as CEO Says Middle-Income Consumers Are Driving Pharma’s ‘Largest New Category Expansion’](https://longbridge.com/en/news/303729491.md) --- > **Disclaimer: This article is for reference only and does not constitute any investment advice.**